5-[(4-Ethoxyanilino)methyl]quinolin-8-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-[(4-Ethoxyanilino)methyl]quinolin-8-ol
• 化学式: C₁₈H₁₈N₂O₂
• 分子量: 294.3
• InChiKey: XIXMMIAXZQPUCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• DISCOVERY OF NOVEL ANTICANCER COMPOUNDS BASED ON CONFORMATIONAL SAMPLING OF QUINOXALINHYDRAZIDE PHARMACOPHORE
  申请人：NEAMATI Nouri

  公开号：US20100160313A1

  公开（公告）日：2010-06-24

  The present invention relates in general to anti-cancer drug design. More specifically, the invention provides methods of mapping and screening for anti-cancer agents using pharmacophore models. The invention demonstrates that, conformational sampling of a small lead molecule, followed by representative pharmacophore model development, is an efficient approach for rational design of novel anticancer agents with similar or better potency than the original lead but with different physicochemical properties.
• COMPOSITIONS AND METHODS FOR TREATING CANCER AND DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160015709A1

  公开（公告）日：2016-01-21

  In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing Growth Factor Inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a Growth Factor inhibitor on a cell, or, a method for re-sensitizing a cell to a Growth Factor Inhibitor, comprising for example, administration of a combination of a TBK1 inhibitor and an RTK inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell. In alternative embodiments, the invention provides compositions and methods for determining: whether an individual or a patient would benefit from or respond to administration of a Growth Factor Inhibitor, or, which individuals or patients would benefit from a combinatorial approach comprising administration of a combination of: at least one growth factor and at least one compound, composition or formulation used to practice a method of the invention, such as an NFKB inhibitor, such as a lenalidomide or a REVLIMID™, or IKK inhibitor; or an inhibitor of Galectin-3.
• US8445677B2
  申请人：——

  公开号：US8445677B2

  公开（公告）日：2013-05-21
• US9632074B2
  申请人：——

  公开号：US9632074B2

  公开（公告）日：2017-04-25
• US9903855B2
  申请人：——

  公开号：US9903855B2

  公开（公告）日：2018-02-27